You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for CY 208-243
CY 208-243 is a centrally active dopamine D1 receptor agonist, selective over D2 receptor sites. Stimulates adenylate cyclase in rat striatal homogenates with an EC50 of 125 nM. Unlike SKF 38393 (Cat. No. 0922), it exerts antiParkinsonian activity in animal models.
Sold with the permission of Novartis Pharma AG
Technical Data for CY 208-243
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for CY 208-243
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for CY 208-243
The following data is based on the product molecular weight 274.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.64 mL||18.22 mL||36.45 mL|
|5 mM||0.73 mL||3.64 mL||7.29 mL|
|10 mM||0.36 mL||1.82 mL||3.64 mL|
|50 mM||0.07 mL||0.36 mL||0.73 mL|
References for CY 208-243
References are publications that support the biological activity of the product.
Andersen and Jansen (1990) DA receptor agonists: selectivity and DA D1 receptor efficacy. Eur.J.Pharmacol. 188 335 PMID: 1973652
Temlett et al (1989) Antiparkinsonian activity of CY 208-243, a partial D-1 DA receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov.Disord. 4 261 PMID: 2571082
Markstein et al (1988) Pharmacologic properties of CY 208-243, a novel D1 agonist. Progress in Catecholamine Research. Part B. Centra 59-64
If you know of a relevant reference for CY 208-243, please let us know.
View Related Products by Product Action
Keywords: CY 208-243, CY 208-243 supplier, Selective, D1-like, agonists, Dopamine, D1, Receptors, D5, dopaminergic, CY208-243, and, 1249, Tocris Bioscience
Citations for CY 208-243
Citations are publications that use Tocris products.
Currently there are no citations for CY 208-243. Do you know of a great paper that uses CY 208-243 from Tocris? Please let us know.
Reviews for CY 208-243
There are currently no reviews for this product. Be the first to review CY 208-243 and earn rewards!
Have you used CY 208-243?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.